glycemic control

Overview

Glycemic control refers to the regulation of blood glucose concentrations within a target range, usually in the context of diabetes and related metabolic disorders. It is a central clinical metric in endocrinology because chronic hyperglycemia is associated with microvascular and macrovascular complications, while excessive glucose lowering increases the risk of hypoglycemia. In practice, glycemic control is assessed using measures such as fasting glucose, postprandial glucose, continuous glucose monitoring metrics, and glycated hemoglobin (HbA1c), depending on the clinical setting and study design.

Biologically, glycemic control reflects the balance among insulin secretion, insulin sensitivity, hepatic glucose production, peripheral glucose uptake, and counterregulatory hormone responses. It is influenced by disease state, treatment intensity, diet, physical activity, body weight, and technologies such as continuous glucose monitors and automated insulin delivery systems. In recent research, glycemic control has been studied not only as an outcome in type 2 diabetes and type 1 diabetes, but also in polycystic ovary syndrome, cystic fibrosis-related diabetes, pregnancy-related hyperglycemia, and other metabolic contexts.

Focus of Latest Publications

Recent publications have used glycemic control as a primary outcome, a stratification variable, or a clinical covariate across a wide range of metabolic and endocrine studies.

Several studies focused on interventions intended to improve glycemic control in diabetes. A randomized controlled trial in women with polycystic ovary syndrome compared two forms of time-restricted eating, eTRE and mTRE, specifically to assess effects on glycemic control, lipid profiles, and weight. In adults with type 2 diabetes in Finland, a nationwide real-world retrospective study evaluated oral semaglutide in GLP-1 receptor agonist–naïve patients and reported effects on glycaemic control, body weight, lipid profile, and liver enzymes. Another real-world study in Hispanic adults with type 2 diabetes examined pharmacological treatment patterns and factors associated with glycemic control alongside renal function parameters, emphasizing that optimal glycemic control is essential to reduce complications.

GLP-1–based therapies were a recurring theme. A report on semaglutide in two adolescents with type 1 diabetes found notable improvements in glycemic control, weight, and insulin requirement after 12 months without adverse events. A separate study of GLP-1 receptor agonists in patients with cancer noted that preclinical studies have linked these agents to reduced tumor progression through downregulation of cellular proliferation pathways and improved glycemic control. Experimental work in diabetic rats using lentiviral GLP-1 gene therapy reported partial restoration of β-cell populations through activation of residual progenitors and stimulation of replication in existing β-cells, improving glycemic control and insulin sensitivity. Another engineered oral delivery system for heterophyllin B in type 2 diabetes was reported to outperform metformin in improving glycemic control, insulin sensitivity, and lipid metabolism, while also improving pancreatic and renal outcomes.

Insulin-based management and glucose monitoring were also prominent. A Cochrane review on insulin regimens for adults with type 1 diabetes aimed to compare benefits and harms of different insulin regimens for achieving optimal glycaemic control while minimizing complications and adverse events. In women with type 1 diabetes, a study of glycemic control during the menstrual cycle evaluated insulin requirements and performance of an automated insulin delivery system, highlighting physiologic variability across the cycle. In adolescents with type 1 diabetes, another cross-sectional study examined factors affecting quality of life and glycemic control. A study in primary care evaluated the use of the FSL2 system and CGM alarm activation in people with type 2 diabetes treated with insulin, focusing on achieved glycemic control. Similarly, a randomized trial of a digital diabetes self-management education and support program integrated with continuous glucose monitoring reported that regular CGM use alongside digital DSMES can improve glycemic control in type 2 diabetes. Telemonitoring studies in poorly controlled type 2 diabetes also noted that telemonitoring has been shown to improve glycemic control, although optimal integration with self-management education remains uncertain.

Glycemic control was also investigated in relation to comorbidity, aging, and functional outcomes. A population-based study in older adults in Korea examined associations between glycaemic control, Blood Pressure, lifestyle behaviors, and sarcopenia. Another study in overweight and obese older adults assessed whether a moderate-intensity multicomponent training program improved body composition, physical function, glycaemic control, and lipid profiles. A protocol for a multimodal exercise program combined with a high-protein diet similarly aimed to determine whether the intervention improves glycaemic control and broader health outcomes. In pre-diabetic older adults, the HEAT trial protocol linked glycemic control and physical function to skeletal muscle capillarization and mitochondrial function, framing impaired glycemic control as part of the path toward type 2 diabetes.

Glycemic control was also examined in disease-specific and life-course contexts. In cystic fibrosis-related diabetes, continuous glucose monitoring was studied for its impact on quality of life and glycaemic control. In pregnancy-related research, maternal hyperglycemia and adult offspring overweight and obesity were analyzed with birthweight as a potential mediator, using maternal glycemic control as the exposure of interest. In dental and musculoskeletal epidemiology, uncontrolled diabetes and tooth loss, as well as glycaemic control and sarcopenia, were investigated as related clinical states. A case series on severe diabetic foot ulcers noted that outcomes varied according to systemic comorbidities, vascular status, and glycemic control, while negative pressure wound therapy supported wound stabilization and preparation for closure.

Mechanistic and translational studies also linked glycemic control to pancreatic biology and glucose toxicity. A JCI Insight study on glucosamine described a hyperglycemia–mTORC1 axis in diabetes, reporting that inhibition of the glucosamine/mTORC1 pathway through SGLT2 inhibition alleviated β-cell stress, improved glycemic control, and restored β-cell function. Another stem cell study found that pancreatic stem-cell-derived islets matured after transplantation into diabetic mice and restored normal glycemic control. A study of a composite gut-liver-pancreas axis-derived index proposed glycemic stratification in type 2 diabetes, suggesting that integrated metabolic markers may improve diagnostic and therapeutic strategies.

Outside diabetes treatment, glycemic control appeared as a broader metabolic and implementation variable. A commentary on early-stage triple-negative breast cancer proposed a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. A study on obesity and medical expenditures among Japanese adults treated for diabetes adjusted analyses for glycemic control, indicating its role as an important confounder or covariate in health economics research. Another study on tooth loss and uncontrolled diabetes in Korean adults noted that the relationship between tooth loss and glycemic control status remains inconclusive.

Overall, these studies position glycemic control as both a therapeutic target and a measurable indicator of metabolic health across diabetes, obesity, reproductive endocrinology, aging, and translational regenerative medicine. The recurring association with semaglutide, tirzepatide, metformin, SGLT2 inhibitors, Insulin Therapy, and continuous glucose monitoring underscores its central role in modern metabolic care.

Key Publications

• Jun Effect of two types of time-restricted eating on glycemic, lipid indices, and weight in women with polycystic ovary syndrome: a randomized controlled trial. (European journal of nutrition, 2026, PMID 42371138): "This study aimed to directly compare the effects of eTRE and mTRE on glycemic control, lipid profiles, and anthropometric outcomes in women with PCOS."
• Jun Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy. (Breast cancer research and treatment, 2026, PMID 42360520): "...propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation."
• Jun Effects of local heat on metabolic health, frailty risk, and exercise adaptations in pre-diabetic older adults: Protocol for the Heat and Exercise in Aging as Therapy (HEAT) clinical trial. (PloS one, 2026, PMID 42296065): "Glycemic control and physical function are supported by SKM capillarization and mitochondrial function, and their impairment contributes to T2D development."
• Jun Lentiviral GLP-1 gene therapy elicits developmental stage-dependent β-cell regeneration in diabetic rats. (Journal of molecular medicine (Berlin, Germany), 2026, PMID 42277427): "In adults, LentiGLP-1 partially restored β-cell populations through activation of residual progenitors and stimulation of replication in existing β-cells, improving glycemic control and insulin sensitivity."
• Jun Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland. (Diabetes, obesity & metabolism, 2026, PMID 42264960): "This Finnish nationwide retrospective 'real-world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP-1 receptor agonists in Finland."
• Jun Glycemic Control During the Menstrual Cycle in Women With Type 1 Diabetes: Performance of an Automated Insulin Delivery System. (Diabetes, obesity & metabolism, 2026, PMID 41877361): "This study aimed to evaluate variations in glycemic control and insulin requirements throughout the menstrual cycle in women with T1D using an automated insulin delivery (AID) system."
• Jun Continuous glucose monitoring for cystic fibrosis-related diabetes: impact on quality of life and glycaemic control. (Diabetes research and clinical practice, 2026, PMID 42019581): "The aim of this study is to establish efficacy and safety of CGM in CFRD to improve glycemic control and quality of life."
• Jun Maternal Hyperglycemia and Adult Offspring Overweight and Obesity: Is Birthweight a Mediator? (American journal of perinatology, 2026, PMID 42049055): "we aimed to evaluate whether the association between maternal glycemic control and adult offspring obesity status was mediated in part through infant birthweight."
• Jun Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes. (Pediatrics, 2026, PMID 42097623): "Both adolescents achieved notable improvements in glycemic control, weight, and insulin requirement after 12 months of treatment without any adverse events."
• Jun Tooth Loss and Uncontrolled Diabetes Among Korean Adults With Type 2 Diabetes: Insights From the Korea National Health and Nutrition Examination Survey (KNHANES) 2014-2018. (Clinical and experimental dental research, 2026, PMID 42143765): "The relationship between tooth loss and glycemic control status in diabetes is inconclusive."